Contact
searchSearch
HMP Global
Quiz

Social Determinants of Health and MASLD/MASH

Rebecca Mashaw
07/18/2025
© 2025 HMP Global. All Rights Reserved.

Related Content

Research Review
High Persistence and Favorable Safety Observed With Resmetirom in Real-World MASH Cohort
05/06/2026
Authors of research presented at Digestive Disease Week concluded that their findings support the “long-term durability, safety, and consistent NIT response of resmetirom in clinical practice.”
Authors of research presented at Digestive Disease Week concluded that their findings support the “long-term durability, safety, and consistent NIT response of resmetirom in clinical practice.”
Authors of research presented at...
05/06/2026
Gastroenterology
Research Review
Tiered MASLD Screening Strategy More Accurate but Misses Significant Fibrosis, Study Finds
05/06/2026
Jessica Garlewicz
A guideline-recommended tiered screening approach for metabolic dysfunction–associated steatotic liver disease (MASLD) may improve overall diagnostic accuracy in primary care but risks missing a substantial proportion of patients with...
A guideline-recommended tiered screening approach for metabolic dysfunction–associated steatotic liver disease (MASLD) may improve overall diagnostic accuracy in primary care but risks missing a substantial proportion of patients with...
A guideline-recommended tiered...
05/06/2026
Gastroenterology
Research Highlights
MAPI Offers New Biomarker in Screening for MetALD and ALD
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
Expert Roundtable
Monitoring Patients With MASLD/MASH
04/17/2026
Nezam Afdhal, MD; Meena Bansal, MD; Zobair Younossi, MD
Our expert roundtable on MASLD/MASH reviews how to monitor patients on treatment for MASLD/MASH, including the use of PEth tests to detect alcohol consumption that may be reducing efficacy of medical therapies.
Our expert roundtable on MASLD/MASH reviews how to monitor patients on treatment for MASLD/MASH, including the use of PEth tests to detect alcohol consumption that may be reducing efficacy of medical therapies.
Our expert roundtable on...
04/17/2026
Gastroenterology

News

Research Review
High Rehospitalization and Mortality Rates Persist After ICI-Associated Colitis
05/06/2026
Jessica Garlewicz
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained common among patients who experienced immune checkpoint inhibitor-associated colitis, indicating that adverse effects often persist beyond ICI exposure.
Rehospitalization remained...
05/06/2026
Gastroenterology
Research Highlights
MAPI Offers New Biomarker in Screening for MetALD and ALD
04/23/2026
Jessica Garlewicz
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index (MAP) proved to be the top-performing model among all commonly used indirect alcohol biomarkers.
MetALD-ALD Prediction Index...
04/23/2026
Gastroenterology
News
Lifetime Alcohol Intake Linked to Colorectal Cancer Risk
02/11/2026
Jessica Garlewicz
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key takeaway is that cumulative alcohol exposure and long-term drinking patterns matter when assessing CRC risk.
For gastroenterologists, the key...
02/11/2026
Gastroenterology
Research Review
New Meta-Analysis Highlights Burden of MASLD Among IBD Patients
02/03/2026
Rebecca Mashaw
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from more than 1.5 million individuals, providing the most extensive evidence yet on MASLD’s prevalence and associated factors in patients with Crohn’s disease and ulcerative colitis.
The study draws on data from...
02/03/2026
Gastroenterology
Emerging Therapies
EC Plus FOLFIRI Improves Response Rates in First-Line BRAF V600E–Mutant Metastatic Colorectal Cancer
01/14/2026
Jessica Garlewicz
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating mCRC, EC plus FOLFIRI offers a highly active first-line strategy for patients with BRAF V600E–mutant disease and may represent a new standard of care in this setting.
For gastroenterologists treating...
01/14/2026
Gastroenterology
Research Highlights
Short Course Radiation and ctDNA for Rectal Cancer
01/14/2026
Jessica Garlewicz
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the ASTRO meeting, investigators indicated that circulating tumor DNA may predict recurrence of rectal cancer following short-course radiation therapy.
In an abstract presented at the...
01/14/2026
Gastroenterology
Research Highlights
Persistent MASLD Greatly Increases Diabetes and Cardiovascular Risks, Study Finds
12/15/2025
Rebecca Mashaw
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links temporal changes in metabolic-associated steatotic liver disease status to markedly different risks for type 2 diabetes, cardiovascular events, and mortality.
A major cohort study links...
12/15/2025
Gastroenterology
Research Highlights
Sex-Specific Risks Highlight MASLD Burden Across Women’s Lifespan
12/11/2025
Rebecca Mashaw
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD disproportionately affects women, with key risks linked to PCOS, menopause, and pregnancy.
A new review details how MASLD...
12/11/2025
Gastroenterology
Conference Coverage
Resmetirom Reduces Portal Hypertension Risk and Fibrosis Markers in MASH Cirrhosis at 2 Years
11/04/2025
Jessica Garlewicz
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients with confirmed F4 fibrosis at baseline demonstrated regression to F3 by year 2 of treatment with resmetirom for MASH cirrhosis.
More than one-third of patients...
11/04/2025
Gastroenterology
Conference Coverage
Tirzepatide Bests Semaglutide in Reducing Cardiovascular Events and Mortality in Patients With MASLD/MASH
11/04/2025
Jessica Garlewicz
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was associated with lower risks of cardiovascular-related outcomes, all-cause mortality, and all-cause hospitalizations compared to semaglutide in a large real-world study, according to an abstract presented at the ACG...
Tirzepatide treatment was...
11/04/2025
Gastroenterology

HMP Global Products

Events

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2026 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Terms of Use